Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that its independently developed, highly selective, oral small-molecule FGFR2/3 inhibitor ABSK061, has been granted Rare Pediatric Disease ("**RPD**") designation by the U.S. Food and Drug Administration ("**FDA**") for the treatment of achondroplasia ("**ACH**").

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK061 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 11 March 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

FDA Granted Rare Pediatric Disease Designation for FGFR2/3 Inhibitor ABSK061

On 11 March 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that its independently developed, highly selective, oral small-molecule FGFR2/3 inhibitor ABSK061, has been granted Rare Pediatric Disease ("**RPD**") designation by the U.S. Food and Drug Administration ("**FDA**") for the treatment of achondroplasia ("**ACH**").

The RPD designation program was established by the FDA to encourage pharmaceutical companies to develop innovative therapies for rare and serious diseases that primarily affect individuals younger than 18 by providing financial incentives, thereby expediting the drug approval process. Based on this RPD designation, if the indication is ultimately approved, Abbisko Therapeutics will have chance to receive a Priority Review Voucher ("**PRV**"), which can be used to expedite the FDA review of another New Drug Application ("**NDA**") or Biologics License Application ("**BLA**"), or transferred to another NDA applicant, thereby carrying significant strategic and commercial value.

ACH is a rare autosomal genetic disorder that causes severe growth and developmental impairments. Research has shown that the pathogenesis of ACH is driven by aberrant activation of the fibroblast Growth Factor Receptor 3 ("**FGFR3**") caused by FGFR3 gene mutations, which suppress normal endochondral ossification[1]. Targeted inhibitors offer the potential to deliver more precise and effective treatment options for ACH patients.

ABSK061, independently developed by Abbisko Therapeutics, is a highly potent and selective small-molecule FGFR2/3 inhibitor. It has demonstrated robust target inhibitory activity, favorable pharmacokinetic properties, and a promising safety profile in preclinical studies. Its oral administration offers significant advantages in terms of convenience and treatment compliance – particularly for pediatric patients – and positions ABSK061 as a potentially valuable therapeutic candidate for children and adolescents with ACH. ABSK061 is currently being evaluated in a Phase II clinical trial in children aged 3 to 12 with ACH.

Reference:

[1] Savarirayan R, et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022 Mar;18(3):173-189.

About ABSK061

ABSK061 is a novel, orally bioavailable, highly potent and selective small molecule inhibitor of FGFR2 and FGFR3 independently discovered and wholly-owned by Abbisko Therapeutics. It is the first FGFR2/3 inhibitor to enter clinical trials globally. First-generation pan-FGFR inhibitors demonstrated clinical efficacy in multiple tumors carrying FGFR2/3 variants and have steadily gained regulatory approval globally. However, the therapeutic window of pan-FGFRs and their clinical efficacy have been limited by side effects associated with FGFR1 inhibition. By reducing FGFR1 activity while maintaining potency against FGFR2 and FGFR3, ABSK061 is expected to achieve a wider therapeutic window with improved clinical efficacy as a new-generation of FGFR inhibitors.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.